Gene · 6839
NIH grants2,112
NIH grants whose papers are about the gene, through NIH's grant-paper links.
181 to 200 of 2,112
Download this page as JSON| Grant | Title | SUV39H1 papers | Newest fiscal year |
|---|---|---|---|
| R01CA183252 | DNMT3A in Development of Hematologic Malignancies | 1 | 2025 |
| R01CA193466 | Computational and Experimental Modeling of Alternative Polyadenylation | 1 | 2025 |
| R01CA199652 | Repression via Facultative Heterochromatin | 1 | 2025 |
| R01CA202919 | Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer | 1 | 2025 |
| R01CA205420 | Enhancing miRNA Therapeutics through Vehicle Free Delivery | 1 | 2025 |
| R01CA207295 | DNA damaging therapy and immune response in small cell lung cancer subtypes | 1 | 2025 |
| R01CA208353 | Elucidation of Human Natural Killer Cell Development | 1 | 2025 |
| R01CA211066 | Intersection of autophagy and vesicle trafficking in Her2-positive breast cancer | 1 | 2025 |
| R01CA233481 | PRECISION METABOLIC THERAPY OF p53 MUTANT TRIPLE NEGATIVE BREAST CANCERS | 1 | 2025 |
| R01CA236356 | Protein arginine methylation in breast cancer | 1 | 2025 |
| R01CA244827 | Regulatory T cells in cancer therapy | 1 | 2025 |
| R01CA247898 | Targeting Epigenomic Regulators at the Replication Fork in PDAC | 1 | 2025 |
| R01CA248984 | DISSECTING THE ROLE OF PRDM15 IN NORMAL HEMATOPOIESIS AND B-CELL MALIGNANCIES | 1 | 2025 |
| R01CA254970 | Novel small molecule USP7 Inhibitors for p53 activation and cancer therapy | 1 | 2025 |
| R01CA257046 | Deciphering and targeting a non-genetic driver pathway in hepatocellular carcinoma | 1 | 2025 |
| R01CA259001 | Targeting mechanisms of immune evasion in chemotherapy-induced senescent cells | 1 | 2025 |
| R01CA259365 | Structure-activity relationships governing mammalian SWI/SNF chromatin remodeling activity as a function of chromatin state | 1 | 2025 |
| R01CA260691 | Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma | 1 | 2025 |
| R01CA261995 | CYP17A1-independent androgen synthesis and prostate cancer resistance to next-generation hormonal therapy | 1 | 2025 |
| R01CA262623 | Systematic Characterization of Small Nucleolar RNAs in Cancer | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6839/grants?page=10